Open Access Repository

Technology evaluation: MRA, Chugai


Downloads per month over past year

Ding, C and Jones, G 2003 , 'Technology evaluation: MRA, Chugai' , Current Opinion in Molecular Therapeutics, vol. 5, no. 1 , pp. 64-69 .

MRA.PDF | Download (52kB)
Available under University of Tasmania Standard License.

| Preview


Chugai, the Japanese subsidiary of Roche, is developing a
humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Type: Article
Authors/Creators:Ding, C and Jones, G
Journal or Publication Title: Current Opinion in Molecular Therapeutics
ISSN: 1464-8431
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page